(News Bulletin 247) – Degroof Petercam announced on Monday that it had initiated coverage of the Aelis Farma share with a buy recommendation and a price target set at 20 euros.

In a note published in the morning, the Belgian investment house supports its opinion with a series of elements, starting with the innovation that it believes the therapeutic approach of the biopharmaceutical company represents.

The Brussels firm particularly retains the promises of its treatment of cannabis addiction and its treatment for cognitive disorders, including in particular those linked to trisomy 21 (Down syndrome).

Degroof Petercam stresses that its proprietary technology platform could be extended to other indications, which suggests that one of its projects could potentially become a ‘blockbuster’, i.e. a drug generating more sales a billion dollars a year.

The brokerage firm thus describes an “attractive investment opportunity” showing a potential upside of 40% since it values ​​the company around 250 million euros, or 20 euros per share.

Copyright (c) 2023 News Bulletin 247. All rights reserved.